News & Updates

In Gleason grade group (GGG) 3 prostate cancer patients with a single intermediate-risk positive biopsy core, risk downgrading appears to be more likely than upgrading, reports a new study.

A recent study has shown clear preferences by urologists when providing postoperative immediate chemotherapy in nonmuscle invasive bladder cancer (NMIBC). Factors beyond clinical variables, such as the structure of the recovery room, play a role in this decision-making process.

Thermal water vapour therapy that consists of a single injection per prostate lobe for benign prostatic hyperplasia (BPH) is both effective and safe, yielding similar improvements in lower urinary tract symptoms and quality of life when compared with a traditional approach that employed variable number of injections by prostate volume, as shown in a study.

Women with endometriosis are more likely to develop various lower urinary tract symptoms, including difficulty passing urine, having to urinate again within minutes of urinating, or still feeling full after urination, a study has found.

An exercise and dietary lifestyle intervention regimen leads to better mobility outcomes among prostate cancer patients undergoing androgen deprivation therapy (ADT) as compared with standard-of-care management, a recent study has found. Moreover, social cognitive outcome measures seem to be predictive of such mobility outcomes.

The risk stratification criteria used in the CHAARTED and LATITUDE trials can accurately assess prognosis in patients with castration-resistant prostate cancer (CRPC), but are insufficient to differentiate between the therapeutic outcomes of androgen receptor pathway inhibitors (ARPI) and docetaxel, a new study has found.

Levels of prostate specific antigen (PSA) mRNA in circulating tumour cells can be used alongside serum PSA protein levels to refine the assessment of disease progression in patient with metastatic castration-resistant prostate cancer (mCRPC), a new study has found.

Oral sitafloxacin was just as effective and safe as levofloxacin for the treatment of complicated and uncomplicated urinary tract infections (UTIs) in adults, according to a phase III study from China.